Market Place
Sourcing Support
Beroni’s Enhanced COVID-19 Antigen Rapid Test Kit Received CE Certification
01 Jun 2022 //
BIOSPACE
Beroni Group Announces Appointment of Dr. John Chiplin to Board of Directors
31 Mar 2022 //
GLOBENEWSWIRE
Beroni Group to Participate in the 2022 Virtual Growth Conference by Maxim Group
23 Mar 2022 //
GLOBENEWSWIRE
Beroni Group sets up new R&D centre in China
03 Feb 2022 //
BIOSPECTRUMASIA
Beroni Group Sets Up a New R&D Centre in High-Tech Hub in Zhuhai, China
31 Jan 2022 //
GLOBENEWSWIRE
Drug developer Beroni Group files for a Nasdaq uplisting
20 Dec 2021 //
RENAISSANCECAPITAL
Beroni Group Received a US$1.07 Million Order for COVID-19 Antigen Test Kits
18 Nov 2021 //
GLOBENEWSWIRE
Beroni Group Published an Article Related to Single-Domain Antibodies in FEBS
28 Oct 2021 //
GLOBENEWSWIRE
Beroni Group Received Approval for 43.5% R&D Rebate from Australian Gov.PENAO
09 Sep 2021 //
YAHOO
Beroni Received Approval for 43.5% R&D Rebate from Australian Govt. for PENAO
09 Sep 2021 //
GLOBENEWSWIRE
Beroni Group Announces Clinical Study of its SARS-CoV-2 Antigen Test Kit
31 Aug 2021 //
GLOBENEWSWIRE
Beroni Begins Manufacture of Anti-Cancer Drug PENAO
19 Aug 2021 //
PRESS RELEASE
Beroni Initiates Manufacture of its Novel, Potential Anti-Cancer Drug PENAO
18 Aug 2021 //
GLOBENEWSWIRE
Beroni, tella Sign MoU for Cancer Immunotherapy Treatment
27 May 2021 //
CONTRACTPHARMA
Beroni Signs Agreement with CDMO Genscript Biotech
12 Aug 2020 //
CONTRACTPHARMA
Beroni Group Provides Update on COVID-19 Nanobody Tech
05 Aug 2020 //
CONTRACTPHARMA
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.